|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:G04BE03
|
|
gptkbp:availableOn
|
gptkb:tablet
oral suspension
injectable solution
|
|
gptkbp:CASNumber
|
gptkb:148553-50-8
|
|
gptkbp:contraindication
|
nitrates
severe cardiovascular disorders
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:hasInChIKey
|
3M7OBD59W3T4GE-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C22H30N6O4S
|
|
gptkbp:hasSMILES
|
CCCN1C2=C(C(=N1)N(C=N2)C)C3=CC(=CC=C3S(=O)(=O)N4CCN(CC4)C)OCC
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
148553-50-8
|
|
gptkbp:IUPACName
|
gptkb:1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:listedOn
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:marketedAs
|
gptkb:Revatio
gptkb:Viagra
|
|
gptkbp:mechanismOfAction
|
PDE5 inhibitor
|
|
gptkbp:meltingPoint
|
189-190°C
|
|
gptkbp:molecularWeight
|
474.6 g/mol
|
|
gptkbp:name
|
gptkb:Sildenafil
|
|
gptkbp:PubChem_CID
|
DB00203
135398744
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
headache
dyspepsia
flushing
visual disturbances
|
|
gptkbp:usedFor
|
erectile dysfunction
pulmonary arterial hypertension
|
|
gptkbp:wasApprovedInYear
|
1998
|
|
gptkbp:bfsParent
|
gptkb:pregabalin
|
|
gptkbp:bfsLayer
|
6
|